A clinical research consultant with a background in academic basic science (transgenics), pharmaceutical industry, technical communication and health-oriented technology.

Transgenics Research

Blouin, MJ., Beauchemin, H., Wright, A. et al. Genetic correction of sickle cell disease: Insights using transgenic mouse models. Nature Medicine 6, 177–182 (2000). https://doi.org/10.1038/72279.

Genetic Correction Of In Vivo Sickling By Fetal Hemoglobin: Implications for Gene Therapy. Blouin M-J, Beauchemin H, Wright A, DePaepe M, Sorette M, Bleau A-M, Nakamoto B, Ou C-N, Stamatoyannopoulos G and Trudel M. Nature Medicine Vol. 6(2); Feb. 2000: 177-182.

PUBMED LINK to Abstract

Also see commentary in News & Views editorial “The first step on the gene therapy pathway to anti-sickling success” by Stefan Karlsson.

RBC oxygen affinity in AγSAD mice | Download Table (researchgate.net)

 Levels Of Fetal Hemoglobin That Affect In Vivo Sickling: Insight From Studies In Transgenic Mice; 11th Conference on Hemoglobin Switching, Orcas, Washington, Oct. 2-6, 1998. (abstract/poster) 
Blouin M-J, Wright A, Beauchemin H, Bleau A-M, Nakamoto B and Trudel M.

Characterization of Fetal Hemoglobin Levels For Genetic Correction Of Sickle Cell Disease In Mice; 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9,1999. (abstract/poster) Blouin M-J, Beauchemin H, Wright A, Bleau A-M, Nakamoto B and Trudel M.

SUPPLEMENTAL

Murine Models of Sickle Cell Disease; in Sickle Cell Disease: Science, Health and Technology Symposium, 3rd Annual Meeting of the National Council of Black Educators in Canada (NCBEC) | Quebec Black Medical Assocation (QBMA) Oct.16-18, 1998.Wright A.

Early Death in Transgenic SAD/Homozygous Alpha Globin Null Mice: A Model for Rapid Assessment of Clinical Benefit in An Anti-sickling Gene Therapy Protocol; A Young Scientists' Conference, NCBEC/ QBMA, Oct. 17, 1998. (abstract/oral presentation) Wright A, Sorette M, Blouin M-J, and Trudel M.